Novel, Anti-Fibrotic

Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF

Veröffentlicht: 17.03.2026 um 20:45 Uhr, prnewswire.co.uk

Arkbio China New York

View original content:https://www.prnewswire.co.uk/news-releases/novel-anti-fibrotic-drug-ak3280-cleared-by-fda-to-initiate-phase-2-proof-of-concept-clinical-trial-in-ipf-302685904.html

en | boerse | 68738396 |